Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on June 11, 2022, with the report date finalized on June 13, 2022. The filing primarily addresses a significant change in corporate leadership and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific separation agreement with the departing CEO:
- Severance Payment: $590,000, payable over a 16-month period commencing within 21 days of June 11, 2022.
- Health Benefits: Company coverage for 12 months of COBRA medical insurance.
- Equity Grant: 400,000 Restricted Stock Units (RSUs) to be issued subject to compliance with the agreement.
Material Changes
The primary material change reported is the resignation of Mr. Martin A. Sumichrast from all positions with the Company, including Chief Executive Officer and member of the Board of Directors, effective June 11, 2022. This resignation was executed pursuant to Section 6(e) of his Employment Agreement dated April 19, 2022.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release on June 13, 2022, confirming the resignation. The Separation Agreement includes customary non-disclosure and non-disparagement provisions, and Mr. Sumichrast has agreed to release the Company from all claims related to his employment.
Equity Vesting Schedule: The 400,000 RSUs granted as part of the separation will vest in two tranches: 200,000 on July 1, 2022, and 200,000 on January 1, 2023. Previously issued and unvested RSUs terminate in accordance with the grants and the Separation Agreement.
Risks and Contingencies: The filing notes that the information regarding the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the appointment of a new Chief Executive Officer and Board member to replace Mr. Sumichrast.
- Review the full text of the Separation Agreement (Exhibit 10.1) for additional covenants or conditions not summarized here.
- Monitor the Company's cash flow to ensure the $590,000 severance and COBRA costs are covered within the specified 21-day commencement window.
- Check subsequent filings for the status of the 400,000 RSUs and any impact on the Company's capital structure.